Literature DB >> 25667460

Vitamin D effect on growth and vitamin D metabolizing enzymes in triple-negative breast cancer.

Sarah E Richards1, Kaytie A Weierstahl1, Jessica L Kelts2.   

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that disproportionately affects women with darker skin. Epidemiological studies indicate that higher vitamin D levels prevent incidence of TNBC and translate to higher survival rates in those that have TNBC.
MATERIALS AND METHODS: The growth inhibition effects of two forms of vitamin D were assessed in MCF-7 and three TNBC lines using CellTiter-Glo. Expression of vitamin D-metabolizing enzymes was measured after vitamin D treatment by quantitative reverse transcription polymerase chain reaction (RT-qPCR).
RESULTS: MCF-7 was growth inhibited by vitamin D at high concentrations but the TNBC lines were not. All cell lines demonstrated large increases in CYP24A1 mRNA levels under vitamin D treatment but there was little change in CYP27B1 or VDR mRNA levels.
CONCLUSION: These TNBC cell lines are resistant to growth inhibition by vitamin D. This could be due to large inactivation of vitamin D by CYP24A1 or by another mechanism. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  25-hydroxyvitamin D; Breast cancer; CYP24A1; CYP27B1; triple-negative breast cancer; vitamin D; vitamin D receptor

Mesh:

Substances:

Year:  2015        PMID: 25667460

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  A Festschrift in Honor of Edward M. Messing, MD, FACS.

Authors:  Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump
Journal:  Bladder Cancer       Date:  2018-10-03

Review 2.  The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms.

Authors:  Meis Moukayed; William B Grant
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

Review 3.  Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer.

Authors:  Xi Zhang; Nadia Harbeck; Udo Jeschke; Sophie Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-26       Impact factor: 4.553

Review 4.  Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy.

Authors:  Janusz Blasiak; Elzbieta Pawlowska; Jan Chojnacki; Joanna Szczepanska; Michal Fila; Cezary Chojnacki
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

Review 5.  Vitamin D: an essential adjuvant therapeutic agent in breast cancer.

Authors:  Romany H Thabet; Adel A Gomaa; Laila M Matalqah; Erin M Shalaby
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

6.  Low CYP24A1 mRNA expression and its role in prognosis of breast cancer.

Authors:  Hongqiao Cai; Yan Jiao; Yanqing Li; Zhaoying Yang; Miao He; Yahui Liu
Journal:  Sci Rep       Date:  2019-09-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.